Roelof van Leeuwen studied pharmaceutical sciences at the Utrecht University for which he received his PharmD degree in 2004. Subsequently, he became a Hospital Pharmacist after internships in the Zaans Medical Center and VU University Medical Center in Amsterdam. In 2012 he started at the Erasmus University Medical Center as a Hospital Pharmacist and PhD student. In 2016 he succesfully defended his thesis “Drug-drug Interactions in patients treated with anti-cancer agents”.
From 2016 till 2019, he was a post-doctoral fellow at the laboratory of translational pharmacology at the department of Medical Oncology. His main research was focused on drug-drug and food-drug interaction studies in oncology. Moreover, there was a special focus and interest on targeted agents like Tyrosine Kinase Inhibitors (TKIs). Incorporating the management of drug-drug interactions in clinical practice and bringing drug interactions studies to the next level were the main challenges during this period.
Since 2019 Roelof has made a switch to the field of research of chemo-efficiency with a primary focus on pharmaco-economics.
In close collaboration with other colleagues Roelof published several peer reviewed papers in clinical journals like Lancet Oncology, Annals of Oncology and the Journal of Clinical Oncology. At this moment Roelof is supervising several (PhD)-students, he is a lecturer at several (university) teaching programs, reviews papers for several journals and is a member of the “Special Interest group Oncology” and the “Dutch Drug Interactions Committee”, a national expert group advising clinicians on the management of drug interactions in oncology.
Field(s) of expertise
- Drug-drug and drug-food interactions in oncology;
- Chemo-efficiency and pharmaco-economics in oncology.
Education and career
- Pharmacy (University of Utrecht).
- Special Interest Group Oncology;
- Dutch Drug Interactions Committee (focus on oncolytics).
Scholarships, grants, and awards
- Coolsingel Stichting;
- Stichting Mitialto;
- Merel Stichting.
- Bayer Pharma;
- Boehringer Ingelheim;